Evidence map›Paper›PMID 27097222›Full record

ArticlemAbs2016

Modeling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion.

Bram G Sengers, Sean McGinty, Fatma Z Nouri, Maryam Argungu, Emma Hawkins, Aymen Hadji, Andrew Weber, Adam Taylor, Armin Sepp

Open access · goldAbstract read
In one paragraph

Article in mAbs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Physiological Considerations for ModelingFrontiers in pharmacology · 2022
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Bram G Sengersa Bioengineering Science Research Group, Faculty of Engineering and the Environment, and Institute for Life Sciences , University of Southampton , Southampton , UK.
Sean McGintyb Division of Biomedical Engineering, Glasgow University , Glasgow , UK.
Fatma Z Nouric Laboratoire de Modélisation Mathématiques et Simulation Numérique, Faculté des Sciences, Université Badji-Mokhtar , Annaba , Algeria.
Maryam Argungud Department of Bioengineering , Imperial College London , London , UK.
Emma Hawkinse Department of Mathematics , University of Surrey , Guildford , UK.
Aymen Hadjif Pharmaceutic Mineral Chemistry Laboratory, Université Badji-Mokhtar , Annaba , Algeria.
Andrew Weberg Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Plc., King of Prussia , PA , USA.
Adam Taylorh Respiratory DPU, GlaxoSmithKline Plc. , Stevenage , UK.
Armin Seppi Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Plc. , Stevenage , UK.
Badji Mokhtar University · DZGlaxoSmithKline (United Kingdom) · GBGlaxoSmithKline (United States) · USImperial College London · GBUniversity of Glasgow · GBUniversity of Southampton · GBUniversity of Surrey · GB

Funding

Biotechnology and Biological Sciences Research Council BB/L020823/1
6 · The paper itself

Abstract

We have developed a mathematical framework for describing a bispecific monoclonal antibody interaction with two independent membrane-bound targets that are expressed on the same cell surface. The bispecific antibody in solution binds either of the two targets first, and then cross-links with the second one while on the cell surface, subject to rate-limiting lateral diffusion step within the lifetime of the monovalently engaged antibody-antigen complex. At experimental densities, only a small fraction of the free targets is expected to lie within the reach of the antibody binding sites at any time. Using ordinary differential equation and Monte Carlo simulation-based models, we validated this approach against an independently published anti-CD4/CD70 DuetMab experimental data set. As a result of dimensional reduction, the cell surface reaction is expected to be so rapid that, in agreement with the experimental data, no monovalently bound bispecific antibody binary complexes accumulate until cross-linking is complete. The dissociation of the bispecific antibody from the ternary cross-linked complex is expected to be significantly slower than that from either of the monovalently bound variants. We estimate that the effective affinity of the bivalently bound bispecific antibody is enhanced for about 4 orders of magnitude over that of the monovalently bound species. This avidity enhancement allows for the highly specific binding of anti-CD4/CD70 DuetMab to the cells that are positive for both target antigens over those that express only one or the other We suggest that the lateral diffusion of target antigens in the cell membrane also plays a key role in the avidity effect of natural antibodies and other bivalent ligands in their interactions with their respective cell surface receptors.

Indexed as

Models, TheoreticalAnimalsAntibodies, BispecificAntibodies, MonoclonalAntibody AffinityDiffusionHumansMonte Carlo MethodAntibodies, BispecificAntibodies, MonoclonalAffinityaviditybispecific antibodydiffusionmodelingMonte Carlosimulationspecificitytherapeutic

Identifiers

PMID27097222
PMCPMC4968105
OpenAlexW2341329630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.